The International Vaccine Institute (IVI) said on Monday that they signed a memorandum of understanding (MOU) with Batavia Bioscience to promote cooperation for vaccine development at IVI headquarters in Seoul, Korea.
Accordingly, both organizations plan to promote cooperation, including joint development of vaccines for global health by actively utilizing IVI’s extensive collaboration experience with global networks and low- and middle-income countries. Additionally, this agreement will take advantage of Batavia’s excellent production facilities.
IVI Secretary-General Jerome Kim and Batavia CEO Menzo Havenga attended the MOU signing ceremony.
Batavia is a biopharmaceutical contract development and manufacturing (CDMO) company headquartered in the Netherlands and acquired by CJ CheilJedang. According to the company’s regulatory filing in November 2021, CJ CheilJedang purchased a 75.8 percent stake in Batavia Biosciences for 267.7 billion won ($215 million) to expand its bio business in the medical and pharmaceutical fields.
Batavia has process development and manufacturing capabilities in next-generation biotherapies including vaccines, oncolytic virotherapies, and cell and gene therapies. Most recently, Batavia developed a vaccine for measles and rubella together with the Institut Pasteur de Dakar (IPD), a non-profit organization in Senegal, reflecting its keen interest in global health issues.
“By combining our core platform technologies in high cell density cultivation and low-cost biopharmaceutical manufacturing with IVI’s global network, we expect to expedite the development of vaccines and capacity onshoring in low- and middle-income countries,” said Havenga.
“We are working to rapidly develop and distribute crucial vaccines by actively utilizing innovative vaccine technologies, to improve global public health,” said Dr. Jerome Kim. “This partnership will facilitate efforts of both organizations to accelerate the development of new vaccines and to create sustainable manufacturing capacity both regionally and globally.”
Kim added that IVI aims to support companies globally to accelerate the clinical development of vaccine candidates against various including infectious diseases cholera, typhoid, chikungunya, shigella, salmonella, schistosomiasis, hepatitis E, HPV, and Covid-19.